Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deep Learning Model for Cetuximab Efficacy in CRLM
NCT05873972Unknown
- Sponsor
- Fudan University
- Start
- Jun 2023
- Primary completion
- Jun 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of cetuximab in colorectal cancer (CRC) (2 arms), sponsored by Fudan University. Primary endpoint: Response Rate at 6 months. Status: unknown.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05873972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05873972.